Navigation Links
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
Date:6/11/2008

ttp://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=CRGN" onClick="var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer. CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Safe Harbor

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the effectiveness of antibody-drug conjugates and CuraGen's CR011-vcMMAE program, including the use of CR011-vcMMAE for metastatic melanoma, breast cancer and gliomas, and the timeframe of initiating clinical trials and presenting results on CR011-vcMMAE may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 More than ... the country will convene in Indianapolis ... (CADCA),s 2015 Mid-Year Training Institute . The week-long ... how to address one of our nation,s biggest public ... CADCA,s Mid-Year Training Institute is a one-of-a-kind intensive training ...
(Date:7/31/2015)... , July 31, 2015 ... Review, 2015 market research report that provides an ... stage using data sourced from in-house databases, secondary ... syringes and needles market products pipeline spread across ... supported with 73 tables and 5 figures is ...
(Date:7/31/2015)... BOSTON , July 31, 2015  Boston ... children benefiting from 3D printing of their anatomy ... had life-threatening cerebrovascular malformations (abnormalities in the brain,s ... Reporting online today in the Journal ... use of 3D printing and synthetic resins to ...
Breaking Medicine Technology:Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 53D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4
... Inc. (NYSE Amex: ANX ) today announced ... acquire SynthRx, Inc. (SynthRx), a private biotechnology company developing ... poloxamer 188 (188). "The acquisition of ... another late-stage asset to our pipeline," stated Brian M. ...
... SANTA CLARA, Calif., Feb. 13, 2011 Samplify ... and sub-systems for the ultrasound equipment market, announced ... company as Senior Scientist, where he will apply ... its next generation of ultrasound beamforming technology and ...
Cached Medicine Technology:ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc. 2ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc. 3ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc. 4ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc. 5ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc. 6Ultrasound Industry Expert, Chris Daft, Joins Samplify Systems 2
(Date:8/3/2015)... ... , ... According to an opinion piece published July 28 by the Washington Post, ... of weight loss may not be accurate. While this system may work for some people, ... varies – based both on the individual and at what point that person is in ...
(Date:8/3/2015)... ... ... Bayer has agreed to pay $56.9 million to set up a settlement ... have suffered an arterial blood clot including stroke and heart attack. The litigation involving ... been ongoing for well-over five years. In 2009, lawsuits filed against Bayer involving Yaz, ...
(Date:8/3/2015)... ... 03, 2015 , ... BESLER Consulting today announced the firm ... The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative ... of their Readmissions Analytics product was selected as one of four finalists in ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... contract research organisations (CROs) for a slew of benefits, allowing them to gain ... operations, boost quality with cost-effective utilisation of resources, get access to innovation and ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent survey by ... of Hispanics believe people can positively affect their diabetes, few look beyond diet ... making diet changes was important. Far fewer participants mentioned the need for exercise ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... depression. But its potential to drive teenagers to suicide ... U.S. Food and Drug Administration (FDA) has proposed that ... box warning on their products' labeling to include warnings ... young adults ages 18 to 24 during initial treatment, ...
... children in Australian are succumbing to infections. And that in ... parents fall back on the day care centres. ... West Australian children found infectious diseases were the most common ... ,Researchers at the Telethon Institute for Child Health Research found ...
... doctors serving in the rural areas have had enough. Most ... in long hours of work . A survey conducted by ... sick of the stress because of the staff shortage, outdated ... the rural area many hospitals and wards have closed down ...
... survival has improved over time. However, for recipients with ... study in the issue of Liver Transplantation. ... liver transplantation in the U.S., however, previous studies have ... to liver transplantation. The difference has become even more ...
... diagnostic technology to detect epidemic diseases has entered the phase ... ,Different from traditional methods that rely on antigen or antibody ... the viruses, namely DNA or RNA, to confirm epidemic diseases ... of the Microarray Centre of US National Institutes of Health ...
... confirmed that the malfunction of a gene causes schizophrenia ... issue of the journal Neuron. ,The researchers said ... for developing treatments for schizophrenia and depression, which have ... researchers. ,In their experiments, the researchers sought ...
Cached Medicine News:Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 3Health News:HCV Patients Survival After Liver Transplantation is Not Improving 2Health News:Malfunction of Gene Causes Schizophrenia, Depression 2
... has greatly enhanced the stabilization ... Biomet Low Profile Tibial Nail ... treatment of unstable fractures, tibial ... pathologic or impending fractures but ...
Arthroscopic instrument system for instability and SLAP fixation....
Arthroscopic instrument system for instability and SLAP fixation....
Suture Cutter, Open Ended, Left Notch...
Medicine Products: